CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT00569127
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:56.908865+00:00
- Published At
- 2016-04-28T00:00:00+00:00
- Record Updated At
- 2026-04-13
- Results Posted At
- 2016-04-28
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Colorectal Neuroendocrine Tumor G1", "Gastric Neuroendocrine Tumor G1", "Neuroendocrine Neoplasm", "Neuroendocrine Tumor", "Neuroendocrine Tumor G2"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"- protocolSection.identificationModule.nctId
"NCT00569127"- protocolSection.identificationModule.officialTitle
"Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2016-04-28"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.